UPCC 26225 A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults with Gastric or Esophageal Cancer (FAPI-GO)

Study of the Use of FAPI-74 PET/CT in Gastric or Esophageal Cancer

Enrolling By Invitation
99 years or below
All
Phase N/A
15 participants needed
1 Location

Brief description of study

This protocol is intended to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging in patients with gastric or esophageal cancer (GEC)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

This study investigates the use of FAPI-74 PET/CT in adults with gastric or esophageal cancer. The purpose is to explore the diagnostic performance of this imaging technique.

The study focuses on evaluating how well FAPI-74 PET/CT detects metastatic disease in these conditions. It assesses the effectiveness and accuracy of this imaging method.

  • Who can participate: Eligibility criteria are to be determined.
  • Study details: Participants will undergo FAPI-74 PET/CT scans to evaluate the imaging technique's performance.
Updated on 03 Aug 2026. Study ID: 25-2115
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator